Skip to main content
SpringerLink
Log in

Expression and Clinical Significance of OX40 and OX40L mRNA in Hepatocellular Carcinoma

  • Published:
Bulletin of Experimental Biology and Medicine Aims and scope

In a retrospective study, the expression of mRNA of membrane receptor OX40 and its ligand OX40L in liver tissues was analyzed in 34 patients with hepatocellular carcinoma in order to assess their clinical implications and prognostic value. Expression of mRNA was analyzed by reverse transcription PCR and TaqMan probes. Expression of OX40 mRNA was significantly higher in tumor specimens in paired comparison with the samples of adjacent non-tumor tissue or normal liver tissue of control patients. In contrast, expression of OX40L mRNA was lower in tumor tissue in paired comparison with the samples of adjacent non-tumor tissue or normal liver tissue. The clinical and pathological analysis showed that expression of OX40 mRNA significantly correlated with the degree of tumor differentiation; there was an insignificant decreasing trend in the length of recurrence-free period. It was hypothesized that microenvironment of hepatocellular carcinoma can induce immunosuppression due to dysregulation of the expression of OX40 and OX40L in tumor tissue, which promotes tumor growth.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A. Rationale for anti-OX40 cancer immunotherapy. Eur. J. Cancer. 2016;52:50-66. doi: https://doi.org/10.1016/j.ejca.2015.08.021

    Article  CAS  PubMed  Google Scholar 

  2. Attanasio J, Wherry EJ. Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease. Immunity. 2016;44(5):1052-1068. doi: https://doi.org/10.1016/j.immuni.2016.04.022

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Buchan SL, Rogel A, Al-Shamkhani A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood. 2018;131(1):39-48. doi: https://doi.org/10.1182/blood-2017-07-741025

    Article  CAS  PubMed  Google Scholar 

  4. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J. Clin. 2016;66(2):115-132. doi: https://doi.org/10.3322/caac.21338

    Article  PubMed  Google Scholar 

  5. Deng J, Zhao S, Zhang X, Jia K, Wang H, Zhou C, He Y. OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer. Onco Targets Ther. 2019;12:7347-7353. doi: https://doi.org/10.2147/OTT.S214211

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. He Y, Zhang X, Jia K, Dziadziuszko R, Zhao S, Deng J, Wang H, Hirsch FR, Zhou C. OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers. Transl. Lung Cancer Res. 2019;8(4):352-366. doi: https://doi.org/10.21037/tlcr.2019.08.15

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Metzger TC, Long H, Potluri S, Pertel T, Bailey-Bucktrout SL, Lin JC, Fu T, Sharma P, Allison JP, Feldman RM. ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection. Cancer Res. 2016;76(13):3684-3689. doi: https://doi.org/10.1158/0008-5472.CAN-15-3412

    Article  CAS  PubMed  Google Scholar 

  8. Shibahara I, Saito R, Zhang R, Chonan M, Shoji T, Kanamori M, Sonoda Y, Kumabe T, Kanehira M, Kikuchi T, So T, Watanabe T, Takahashi H, Iwabuchi E, Tanaka Y, Shibahara Y, Sasano H, Ishii N, Tominaga T. OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy. Mol. Cancer. 2015;14:41. doi: https://doi.org/10.1186/s12943-015-0307-3

  9. Virani NA, Thavathiru E, McKernan P, Moore K, Benbrook DM, Harrison RG. Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018;425:174-182. doi: https://doi.org/10.1016/j.canlet.2018.03.027

    Article  CAS  PubMed  Google Scholar 

  10. Wang Z, Zhang N, Song R, Fan R, Yang L, Wu L. Activin A expression in esophageal carcinoma and its association with tumor aggressiveness and differentiation. Oncol. Lett. 2015;10(1):143-148. doi: https://doi.org/10.3892/ol.2015.3248

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Webb GJ, Hirschfield GM, Lane PJ. OX40, OX40L and Autoimmunity: a Comprehensive Review. Clin. Rev. Allergy Immunol. 2016;50(3):312-332. doi: https://doi.org/10.1007/s12016-015-8498-3

    Article  CAS  PubMed  Google Scholar 

  12. Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Urba WJ, Curti BD. Science gone translational: the OX40 agonist story. Immunol. Rev. 2011;244(1):218-231. doi: https://doi.org/10.1111/j.1600-065X.2011.01069.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wu CJ, Tsai YT, Lee IJ, Wu PY, Lu LS, Tsao WS, Huang YJ, Chang CC, Ka SM, Tao MH. Combination of radiation and interleukin 12 eradicates large orthotopic hepatocellular carcinoma through immunomodulation of tumor microenvironment. Oncoimmunology. 2018;7(9):e1477459. doi: https://doi.org/10.1080/2162402X.2018.1477459

    Article  PubMed  PubMed Central  Google Scholar 

  14. Zhong B, Huang MP, Yin GQ, Gao X. Effects of costimulation on intrahepatic immunopathogenesis in patients with chronic HBV infection. Inflamm. Res. 2014;63(3):217-229. doi: https://doi.org/10.1007/s00011-013-0691-3

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Laboratory of Emergency Medicine, Tianjin Union Medical Centre, Tianjin, P.R. China

    P. Du

  2. Department of Pathology, Tianjin First Central Hospital, Tianjin, P.R. China

    Z. Wang

  3. Department of Clinical Laboratory, 2nd Hospital of Tianjin Medical University, Tianjin, P.R. China

    J. Geng & Y. Wang

Authors
  1. P. Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Geng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y. Wang.

Additional information

Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 170, No. 10, pp. 499-503, October, 2020

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Du, P., Wang, Z., Geng, J. et al. Expression and Clinical Significance of OX40 and OX40L mRNA in Hepatocellular Carcinoma. Bull Exp Biol Med 170, 485–488 (2021). https://doi.org/10.1007/s10517-021-05093-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10517-021-05093-8

Key Words

Search

Navigation